Eagle Pharmaceuticals (EGRX)
(Real Time Quote from BATS)
$4.13 USD
-0.03 (-0.72%)
Updated Apr 29, 2024 02:54 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EGRX 4.13 -0.03(-0.72%)
Will EGRX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for EGRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EGRX
Down -33.75% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround
Down -26.73% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround
EGRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Canopy Growth Corporation (CGC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Implied Volatility Surging for Eagle Pharmaceuticals (EGRX) Stock Options
4 Undervalued Medical Stocks to Buy Amid High Market Volatility
Other News for EGRX
Eagle Pharmaceuticals says unlikely to file Form 10-Q or 10-K by May 13
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
Eagle Pharmaceuticals to present data from Phase III trial of amisulpride
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report onĀ Form 10-K
HROW, HCAT and EGRX are among after hour movers